AI-Designed Drug Rentosertib Shows Early Signs of Slowing Biological Aging in Lung Disease Trial

Key points

• Insilico Medicine’s AI-designed drug rentosertib reduced biological age markers in 42 patients with idiopathic pulmonary fibrosis over 12 weeks, according to a study in Nature Biotechnology.
• The trial used six different proteomic aging clocks, all of which showed a statistically significant decrease in the pace of aging for treated participants compared to placebo.
• Rentosertib was originally developed to treat chronic lung disease, but Insilico designed it with the dual goal of also extending lifespan by targeting aging hallmarks.
• The study found that improvements in lung function did not fully explain the reduction in biological age, suggesting the drug may have independent anti-aging effects.
• Researchers caution that aging clocks are not yet universally accepted metrics, and the drug requires further trials before it can be approved for any use.

Background

This development follows a series of 2026 studies exploring how diet and existing drugs might influence aging. For instance, a USC study suggested that a low-protein, methionine-supplemented diet improved healthspan in mice, while a separate review indicated that reducing protein intake might benefit sedentary adults. Additionally, research on sildenafil (Viagra) suggested it might slow cancer spread by disrupting cholesterol transport, highlighting the growing interest in repurposing existing compounds for longevity and disease prevention.

How outlets are covering it

Gizmodo and The New York Times both highlight the potential of AI in drug discovery but emphasize the preliminary nature of the findings. Gizmodo notes that aging clocks are still debated and may not accurately reflect true health, while The New York Times focuses on the dual-purpose design of the trial. The Nature Biotechnology study provides the technical detail, showing that proteomic clocks are more accurate than epigenetic ones for this purpose but cannot fully separate aging effects from disease-specific improvements. FirstWord Pharma’s content was inaccessible due to a JavaScript challenge, so no perspective could be extracted from that source.

Why it matters

This study represents a significant step toward using AI to design drugs that target aging itself, not just specific diseases. If validated, rentosertib could pave the way for a new class of geroprotective therapies. However, the lack of a universally accepted aging metric and the need for further clinical trials mean that this is still an early-stage development with significant hurdles to overcome before it can impact patient care.

What to watch

Insilico Medicine will need to conduct further trials to validate the anti-aging effects of rentosertib in healthy volunteers and to separate these effects from its anti-fibrotic activity. Regulatory approval will depend on demonstrating clear benefits for both lung disease and aging, which is a complex and unprecedented challenge. The scientific community will also need to continue refining aging clocks to ensure they provide reliable and meaningful data for clinical trials.